General
Preferred name
AMISULPRIDE
Synonyms
Amisulpride (hydrochloride) ()
DAN 2163 hydrochloride ()
DAN 2163 ()
DAN-2163 ()
Amisulpride hydrochloride ()
Deniban ()
Solian 200 ()
NSC-760085 ()
APD-421 ()
Sulamid ()
Aminosultopride ()
APD421 ()
Barhemsys ()
Solian ()
Solian 100 ()
Socian ()
Solian 400 ()
Solian 50 ()
Amisulpride-d5 ()
P&D ID
PD001316
CAS
71675-85-9
53583-79-2
81342-13-4
1216626-17-3
Tags
natural product
drug
available
Approved by
FDA
First approval
2020
1986
Drug Status
investigational
approved
Drug indication
Schizophrenia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The approved drug amisulpride is a racemic mixture of (+)-amisulpride and (-)-amisulpride. The structure shown here does not specify stereochemistry and represents the mixture. The links to external resources in the table above all match the INN-assigned compound amisulpride without stereochemistry specified. Alternative stereoisomers are represented by CID 5746246 and CID 3055076.

The INN-assigned compound sultopride has a similar but distinct structure to amisulpride; however the nomenclature for these two compounds is sometimes used interchangeably on other resources. (GtoPdb)
DESCRIPTION Selective P2Y6 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Selective D2/D3 receptor antagonist; atypical antipsychotic agent (Tocriscreen Total)
DESCRIPTION Amisulpride hydrochloride could inhibit radioligand binding to native dopamine D2 receptor in membranes from the rat striatum with an IC50 value of 21nM. It has been revealed to displace [3H]raclopride binding in vivo with an ED50 value of 17.3±1.86mg/kg in the rat limbic system. It has been noted to inhibit quinpirole-induced [3H]thymidine with an IC50 value of 22±3nM. It is used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. It has been approved in February 2002 by FDA. (BOC Sciences Bioactive Compounds)
Compound Sets
28
AdooQ Bioactive Compound Library
A10067
Axon Medchem Screening Library
1381
BOC Sciences Bioactive Compounds
amisulpride-hydrochloride-cas-81342-13-4-item-474848
Cayman Chemical Bioactives
14619
30075
ChEMBL Approved Drugs
CHEMBL243712
ChEMBL Drugs
CHEMBL243712
DrugBank
DB06288
DrugBank Approved Drugs
DB06288
DrugCentral
179
DrugCentral Approved Drugs
179
DrugMAP
DMSJVAM
DrugMAP Approved Drugs
DMSJVAM
DrugMatrix
Guide to Pharmacology
963
Ki Database
Amisulpride
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL243712
MedChem Express Bioactive Compound Library
HY-14545
NCATS Inxight Approved Drugs
8110R61I4U
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Amisulpride
TargetMol Bioactive Compound Library
T0811
The Spectrum Collection
Tocris Bioactive Compound Library
2132
Tocriscreen Total
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
369.17
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
1
cLogP
1.29
TPSA
101.73
Fraction CSP3
0.59
Chiral centers
1.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dopamine Receptor
5-HT
dopamine
D2/3 antagonist
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Primary Target
Non-selective Dopamine
MOA
Antagonist
Dopamine D2 Antagonists
Dopamine D3 Antagonists
Member status
member
Therapeutic Class
Antipsychotic Agents
Solubility
DMSO 74 mg/mL
Water <1 mg/mL
Ethanol 74 mg/mL
Source data